TickerGuard
Buy Day today: Poor (57) Mixed market breadth · today: Nonfarm Payrolls (September)
SPTX

Seaport Therapeutics, Inc.

Healthcare · Biotechnology

19.00$ -6.0% vs. previous close Closing price · As of: Oct 1, 2026

Ownership

Ownership Structure

Who owns Seaport Therapeutics, Inc. (SPTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 34.4% of the shares are freely tradable; institutional investors hold 43.0%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 43.0%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 35.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 34.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 6.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 54Mio.

Largest Shareholders

Institutions

Institutions SPTX
Name Stake (%) Shares Change (%) Date
ARCH VENTURE CORP 11.76 6,294,951 +0.0 06/30/2026
General Atlantic Llc 11.40 6,101,582 +0.0 06/30/2026
Sofinnova Ventures 6.66 3,564,871 +0.0 06/30/2026
Goldman Sachs Asset Management, L.P. 4.07 2,178,642 +0.0 06/30/2026
TRV GP VI, LLC 3.85 2,061,222 +0.0 06/30/2026
Canada Pension Plan Investment Board 3.69 1,975,791 +0.0 06/30/2026
JPMorgan Chase & Co 3.39 1,815,845 +0.0 06/30/2026
Foresite Capital Management VI LLC 3.32 1,779,521 +0.0 06/30/2026
T. Rowe Price Associates, Inc. 2.44 1,308,604 +0.0 06/30/2026
FMR Inc 2.21 1,185,100 +0.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?